Kite, a division of Gilead Sciences (NASDAQ:GILD), and Arcellx (NASDAQ:ACLX) will begin a phase 3 study of their CAR-T multiple myeloma treatment anitocabtagene autoleucel (anito-cel) in the H2 ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...

Kite’s CAR T-cell products are heading toward approval alongside those from Novartis, whose CTL019 therapy to treat acute lymphoblastic leukemia recently got two thumbs up from a US Food and Drug ...

Gilead is spending $12 billion to buy Kite Pharma, a biotech that has no approved therapies yet. The drugmaker's therapy that's a few months away from a possible approval is a highly personalized ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today, I have the pleasure of talking, about cancer with Cindy, who's the Head of Kite. And thank you ...